Bladder Cancer News and Research

Latest Bladder Cancer News and Research

Fujikura to exercise option to license Cellmid’s midkine diagnostic technology

Cellmid Limited has received confirmation that Fujikura Kasei Co Ltd (Fujikura) will exercise its Option to licence the midkine (MK) diagnostic technology by paying the requisite JPY40 million (AUD 440,000) Milestone Fee.

22 Jul 2013

OncoGenex completes enrollment in OGX-427 Phase 2 trial for treatment of metastatic bladder cancer

OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.

16 Jul 2013

Bioniche, Paladin close debt refinancing agreement and sign first licensing deal for Urocidin

Bioniche Life Sciences Inc. and Paladin Labs Inc. today announced the official closing of the various agreements associated with a comprehensive strategic collaboration to refinance and increase Bioniche's debt, provide new equity, and enter into the first licensing deal for Bioniche's Phase III bladder cancer product - Urocidin.

6 Jul 2013

Sorrento, IGDRASOL to present updates on IG-001 and IG-004 at joint meeting of CLINAM and ETPN

Sorrento Therapeutics, Inc. and IGDRASOL announced today that the companies will present updates of their analyses of proprietary late clinical stage paclitaxel formulations, IG-001 (Cynviloq) and IG-004 (TOCOSOL paclitaxel) at the joint meeting of the European Foundation for Clinical Nanomedicine and the European Technology Platform on Nanomedicine in Basel, Switzerland on June 23 - 26.

21 Jun 2013

Novel abnormalities in FGFR gene identified in a spectrum of cancers

Novel abnormalities in the FGFR gene, called FGFR fusions, were identified in a spectrum of cancers, and preliminary results with cancer cells harboring FGFR fusions suggested that some patients with these cancers may benefit from treatment with FGFR inhibitor drugs, according to data published in Cancer Discovery, a journal of the American Association for Cancer Research.

10 Jun 2013

Instillation of chemotherapy can minimize recurrence and progression of bladder cancer

Researchers at UCLA's Jonsson Comprehensive Cancer Center led by Dr. Karim Chamie have found that more intense surveillance and treatment of bladder cancer in the first two years after diagnosis could reduce the number of patients whose cancer returns after treatment and lower the disease's death rate. The study was published online ahead of press today in the journal Cancer.

6 Jun 2013

Research shows PODXL protein contributes to aggressive forms of bladder cancer

Aggressive forms of bladder cancer involve the protein PODXL - a discovery that could hold the key to improved treatment, according to researchers at Lund University, Uppsala University and KTH in Sweden.

24 May 2013

Exosome Diagnostics' urine exosome technology accurately predicts outcome of prostate biopsy

Exosome Diagnostics, a leading developer of biofluid-based molecular diagnostic products for use in personalized medicine research and clinical diagnostics, today announced the presentation of data at the American Urological Association Annual Meeting in San Diego demonstrating the performance of urine exosome technology in accurately predicting the outcome of a prostate biopsy.

9 May 2013

Study: Patients are more likely to have recurrence of cancer after bladder removal

Patients with advanced bladder cancers that are surgically removed might need additional therapy to prevent recurrence in certain situations, a new UT Southwestern Medical Center study suggests.

8 May 2013

Pancreatitis and diabetes drugs: an interview with Dr Sonal Singh, Johns Hopkins University School of Medicine

Acute pancreatitis is an inflammation of the pancreas which leads to leakage of pancreatic enzymes. Apart from certain drugs such as GLP-1 based therapies, the most common causes of pancreatitis are Gallstones and Alcohol use.

30 Apr 2013

iQBS researchers discover three unique genetic variations that influence body size, obesity in African ancestry

Researchers from Dartmouth's Institute for Quantitative Biomedical Sciences (iQBS) and the Center for Genomic Medicine have helped to discover three unique genetic variations that influence body size and obesity in men and women of African ancestry.

23 Apr 2013

Palliative radiotherapy for bone metastases can improve quality of life in elderly patients

Giving palliative radiotherapy to elderly patients with painful bone metastases can significantly improve their quality of life, a Dutch researcher told the 2nd Forum of the European Society for Radiotherapy and Oncology (ESTRO) today (Monday).

23 Apr 2013

Aeterna enters into agreements to transfer manufacturing license for Cetrotide to Merck KGaA

Aeterna Zentaris Inc. today announced that its German subsidiary has entered into binding agreements with various partners and licensees with respect to the manufacturing rights and obligations for its Cetrotide® product.

22 Apr 2013

Preclinical studies show bladder cancers, mesotheliomas respond to treatment with ADI-PEG 20

Scientists from academic institutions reported at the 2013 annual American Association for Cancer Research meeting, results from preclinical studies which showed that certain bladder cancers and mesotheliomas have metabolic changes and are more likely to respond to treatment with ADI-PEG 20 (pegylated arginine deiminase) if they are deficient in the enzyme, argininosuccinate synthetase.

18 Apr 2013

Study shows hsa-miR-146a overexpressed in most metastatic tumors

In order to kill, bladder cancer must metastasize, most commonly to the lung - what are the differences between bladder cancers that do and do not make this deadly transition? Research presented by the Director of the University of Colorado Cancer Center at the AACR Annual Meeting 2013 shows that one big difference is a little molecule known as hsa-miR-146a.

11 Apr 2013

BIND Therapeutics presents positive Phase 1 clinical study results for BIND-014 at AACR meeting

BIND Therapeutics, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called AccurinsTM, announced today that positive Phase 1 clinical data for BIND-014, the company's lead drug candidate, were presented today in an oral presentation at the American Association for Cancer Research 2013 Annual Meeting.

10 Apr 2013

Sorrento Therapeutics, IGDRASOL to present updates on Cynviloq at Nanomedicine 2013 meeting

Sorrento Therapeutics, Inc. and IGDRASOL announced today that IGDRASOL will be presenting updates of its analysis of proprietary late clinical stage NBN-Pac formulations, namely IG-001 (Cynviloq) and IG-004 (a D-a-tocopheryl polyethylene glycol succinate (TPGS)-based paclitaxel formulation) at the annual Nanomedicine 2013 meeting in Barcelona, Spain (April 11th - 12th).

8 Apr 2013

First patient dosed in second Phase 2 study with LiRIS for treatment of Interstitial Cystitis

TARIS Biomedical, a specialty pharmaceutical company developing innovative, targeted therapies to treat bladder diseases with high unmet medical need, announced today that it has dosed the first patient in its second Phase 2 clinical study with LiRIS, its novel product candidate, in patients with Interstitial Cystitis.

3 Apr 2013

Engineers develop prototype telerobotic platform for bladder cancer treatment

Although bladder cancer is the sixth most common form of cancer in the U.S. and the most expensive to treat, the basic method that doctors use to treat it hasn't changed much in more than 70 years.

3 Apr 2013

IGDRASOL to present updates on Cynviloq at AACR annual meeting

Sorrento Therapeutics, Inc. and IGDRASOL announced today that IGDRASOL will be presenting updates of its development of Cynviloq (IG-001) at the annual meeting of the American Association for Cancer Research in Washington, DC (April 6th to 10th).

1 Apr 2013

Bladder Cancer News and Research

Latest Bladder Cancer News and Research

Fujikura to exercise option to license Cellmid’s midkine diagnostic technology

OncoGenex completes enrollment in OGX-427 Phase 2 trial for treatment of metastatic bladder cancer

Bioniche, Paladin close debt refinancing agreement and sign first licensing deal for Urocidin

Sorrento, IGDRASOL to present updates on IG-001 and IG-004 at joint meeting of CLINAM and ETPN

Novel abnormalities in FGFR gene identified in a spectrum of cancers

Instillation of chemotherapy can minimize recurrence and progression of bladder cancer

Research shows PODXL protein contributes to aggressive forms of bladder cancer

Exosome Diagnostics' urine exosome technology accurately predicts outcome of prostate biopsy

Study: Patients are more likely to have recurrence of cancer after bladder removal

Pancreatitis and diabetes drugs: an interview with Dr Sonal Singh, Johns Hopkins University School of Medicine

iQBS researchers discover three unique genetic variations that influence body size, obesity in African ancestry

Palliative radiotherapy for bone metastases can improve quality of life in elderly patients

Aeterna enters into agreements to transfer manufacturing license for Cetrotide to Merck KGaA

Preclinical studies show bladder cancers, mesotheliomas respond to treatment with ADI-PEG 20

Study shows hsa-miR-146a overexpressed in most metastatic tumors

BIND Therapeutics presents positive Phase 1 clinical study results for BIND-014 at AACR meeting

Sorrento Therapeutics, IGDRASOL to present updates on Cynviloq at Nanomedicine 2013 meeting

First patient dosed in second Phase 2 study with LiRIS for treatment of Interstitial Cystitis

Engineers develop prototype telerobotic platform for bladder cancer treatment

IGDRASOL to present updates on Cynviloq at AACR annual meeting

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Bladder Cancer News and Research

Latest Bladder Cancer News and Research

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in